Merck Releases Positive Study For Vytorin, But How Much Impact Will It Have?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck & Co. is ready to move forward with a new submission for Vytorin for treatment of chronic kidney disease patients, having finally gathered positive study results for a cholesterol-lowering drug in the high-risk patient population.